Claims for Patent: 10,751,349

Summary for Patent: 10,751,349

Title:	Compositions of obeticholic acid and methods of use
Abstract:	The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
Inventor(s):	Lancaster; Richard Gail (San Diego, CA), Olmstead; Kay K. (Escondido, CA), Kagihiro; Masashi (Suita, JP), Matono; Mitsuhiro (Osaka, JP), Taoka; Ikuko (Toyonaka, JP), Pruzanski; Mark (New York, NY), Shapiro; David (Rancho Santa Fe, CA), Hooshmand-Rad; Roya (San Diego, CA), Pencek; Richard (San Diego, CA), Sciacca; Cathi (San Diego, CA), Eliot; Lise (San Diego, CA), Edwards; Jeffrey (San Diego, CA), MacConell; Leigh A. (Encinitas, CA), Marmon; Tonya K. (San Diego, CA)
Assignee:	Intercept Pharmaceuticals, Inc. (New York, NY)
Application Number:	16/248,512
Patent Claims:	1. A tablet comprising obeticholic acid in an amount of 1 mg to 50 mg and a pharmaceutically acceptable excipient, wherein said obeticholic acid is in the form of jet-milled particles having a diameter of less than about 100 .mu.m when analyzed by laser diffraction, and wherein D.sub.50 is not more than 50 .mu.m, and wherein the pharmaceutically acceptable excipient has a total primary alcohol impurity of less than about 6% (wt/wt). 2. The tablet of claim 1, wherein D.sub.50 is not more than 20 .mu.m. 3. The tablet of claim 1, wherein D.sub.50 is not more than 10 .mu.m. 4. The tablet of claim 1, wherein the tablet comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises said obeticholic acid and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient. 5. The tablet of claim 4, wherein the extra-granular portion does not contain obeticholic acid. 6. The tablet of claim 1, wherein said pharmaceutically acceptable excipient having a total primary alcohol impurity of less than about 6% (wt/wt) is sodium starch glycolate. 7. The tablet of claim 5, wherein the intra-granular portion comprises a diluent selected from: starch, pregelatinized starch, microcrystalline cellulose, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium phosphate, lactose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, simethicone, sodium chloride, talc, xylitol, sorbitol, mannitol, and sucrose, and/or a combination thereof. 8. The tablet of claim 5, wherein the extra-granular portion comprises a diluent selected from: starch, pregelatinized starch, microcrystalline cellulose, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium phosphate, lactose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, simethicone, sodium chloride, talc, xylitol, sorbitol, mannitol, and sucrose, and/or a combination thereof. 9. The tablet of claim 7, wherein the diluent is microcrystalline cellulose. 10. The tablet of claim 9, wherein a ratio of microcrystalline cellulose to obeticholic acid in the intra-granular portion is from about 20:1 to about 1:5. 11. The tablet of claim 10, wherein the ratio is from about 20:1 to about 1:1. 12. The tablet of claim 11, wherein the ratio is from 20:1 to about 5:1. 13. The tablet of claim 5, wherein the tablet comprises 5 mg of obeticholic acid. 14. The tablet of claim 5, wherein the tablet comprises 10 mg of obeticholic acid. 15. The tablet of claim 5, wherein the tablet comprises 25 mg of obeticholic acid. 16. The tablet of claim 1, wherein the pharmaceutically acceptable excipient has a total primary alcohol impurity of less than about 3% (wt/wt). 17. The tablet of claim 1, wherein the pharmaceutically acceptable excipient has a total primary alcohol impurity of less than about 0.5% (wt/wt). 18. The tablet of claim 1, wherein D.sub.50 is not more than 5 .mu.m. 19. A tablet comprising: obeticholic acid in an amount of 1 mg to 50 mg; and sodium starch glycolate, wherein said obeticholic acid is in the form of jet-milled particles having a diameter of less than about 100 .mu.m when analyzed by laser diffraction, wherein D.sub.50 is not more than 50 .mu.m, and wherein the total alcohol impurity in said sodium starch glycolate is less than about 6% (wt/wt). 20. The tablet of claim 19, wherein D.sub.50 is not more than 5 .mu.m. 21. The tablet of claim 19, wherein the total alcohol impurity in said sodium starch glycolate is less than about 3% (wt/wt). 22. The tablet of claim 19, wherein the total alcohol impurity in said sodium starch glycolate is less than about 0.5% (wt/wt).